M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Completed

Conditions: Leukemia
Acute Lymphoblastic Leukemia
Allogeneic Haematopoietic Stem Cell Transplantation
Lymphoma

Interventions: Drug: Busulfan
Drug: Clofarabine
Drug: Thymoglobulin
Procedure: Stem Cell Transplant

First Posted Date: 2009-10-06

Last Posted Date: 2018-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT00990249

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Doctor-Recommended Home-Based Exercise Program or Relaxation Training in Improving Physical Function and Controlling Symptoms in Patients With Stage IV or Recurrent Colon Cancer That Cannot Be Removed By Surgery

Not Applicable

Conditions: Colorectal Cancer

Interventions: Behavioral: Exercise Program
Behavioral: Telephone-based intervention
Other: Counseling intervention
Other: Questionnaire administration
Behavioral: Relaxation Program

First Posted Date: 2009-09-28

Last Posted Date: 2022-03-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 154

Registration Number: NCT00985400

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Reducing Tobacco Related Health Disparities

Not Applicable

Completed

Conditions: Smoking Cessation
Smoking

Interventions: Behavioral: Standard Treatment (ST)
Behavioral: Telephone Counseling
Behavioral: Quitline
Behavioral: Nicotine Replacement Therapy (NRT)

First Posted Date: 2009-09-25

Last Posted Date: 2016-10-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 639

Registration Number: NCT00984724

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Procedure: Surgery
Radiation: Chest Irradiation
Drug: Cisplatin
Drug: Etoposide
Radiation: Prophylactic Cranial Irradiation

First Posted Date: 2009-09-25

Last Posted Date: 2016-06-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 38

Registration Number: NCT00984997

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Celecoxib as a Chemopreventive Agent in Current and Former Smokers

Phase 3

Completed

Conditions: Smoking
Prevention

Interventions: Drug: Celecoxib
Drug: Placebo

First Posted Date: 2009-09-22

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 219

Registration Number: NCT00981201

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver

Phase 1

Completed

Conditions: Liver Cancer
Advanced Cancer

Interventions: Drug: Irinotecan
Drug: Bevacizumab
Drug: Oxaliplatin
Drug: Cetuximab

First Posted Date: 2009-09-21

Last Posted Date: 2015-11-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 115

Registration Number: NCT00980239

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Infusion of Expanded Cord Blood T Cells

Phase 1

Withdrawn

Conditions: Stem Cell Transplantation
Leukemia
Lymphoma
Pediatric Disorders

Interventions: Drug: Melphalan
Radiation: Total Body Irradiation (TBI)
Drug: Thiotepa
Drug: Fludarabine
Drug: Etoposide
Drug: Rituximab
Drug: Anti-thymocyte globulin (ATG)
Drug: Mycophenolate Mofetil (MMF)
Drug: Tacrolimus
Procedure: Cord Blood Infusion
Drug: G-CSF
Procedure: Ex vivo expanded T cell Infusion

First Posted Date: 2009-09-04

Last Posted Date: 2012-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00972101

Discount Generic Prescription Study

Completed

Conditions: Poverty
Low-Income Population

Interventions: Behavioral: Survey
Behavioral: Focus Group

First Posted Date: 2009-09-03

Last Posted Date: 2012-04-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 574

Registration Number: NCT00971022

Locations: 🇺🇸
Independence Heights Community Health Center, Houston, Texas, United States
🇺🇸
Second Mile Mission Center, Houston, Texas, United States
🇺🇸
HOPE Clinic, Houston, Texas, United States

Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: Temozolomide
Drug: Abraxane
Drug: Cisplatin
Biological: Interleukin-2
Biological: Interferon alpha 2b

First Posted Date: 2009-09-03

Last Posted Date: 2013-01-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00970996

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

Phase 1

Completed

Conditions: B-cell Lymphoma
Lymphoma

Interventions: Procedure: Leukapheresis
Procedure: Stem Cell Transplant
Procedure: CD19-specific T Cell Infusion
Drug: Carmustine
Drug: IL-2
Drug: Etoposide
Drug: Melphalan
Drug: Cytarabine

First Posted Date: 2009-08-31

Last Posted Date: 2023-12-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT00968760

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy